Parkland Health
Dallas, Texas, 75235, United States
Location contact
Arthur Hong, MD
CONTACT
Kathryn Anderson, MA
CONTACT
NCT Number: NCT07550192
This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health.
Eligible patients will be randomized to either a control (usual care) arm or an intervention arm. If a patient in the control group has experiences a subsequent cancer treatment related ED visit without documented OAC engagement, they will be moved to the intervention arm. Patients in the intervention arm will receive an automated MyChart message and text message within 24 hours of hospital discharge reinforcing oncology acute care (OAC) resources, including contact information for the triage line and guidance for when to seek urgent versus emergency care. Messages will be resent at 48 and 72 hours if unviewed. Once the message is viewed, the patient will enter an outcome tracking period to monitor time to subsequent ED visit or OAC contact. Follow-up will occur in 3-month intervals until an outcome is documented or the study ends.
After randomization, patients will be monitored on an observation list for outcomes including OAC contact and cancer treatment-related Emergency Department (ED) visits. Patients who contact OAC clinic will be removed from observation list and complete the study. We will repeat the observation period and document outcomes if the patient has a subsequent cancer treatment-related ED visits without documented OAC engagement.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Dallas, Texas, 75235, United States
Arthur Hong, MD
CONTACT
Kathryn Anderson, MA
CONTACT
Overview:
This study is a pragmatic randomized controlled crossover trial designed to evaluate the feasibility and impact of structured follow-up messaging interventions on patient engagement with Oncology Acute Care (OAC) services and reduction in cancer treatment-related Emergency Department (ED) visits at Parkland Health.
Recruitment and Enrollment:
Eligible patients will be identified using an automated dashboard through Parkland's Epic electronic health record system based on the inclusion/Exclusion criteria. Patients meeting criteria will be automatically flagged for study enrollment. No active consent will be required as the intervention involves standard communication methods already available to patients (MyChart and text messaging), and the study poses minimal risk.
Randomization and Crossover Design:
Patients will be randomized into one of two arms:
Control Arm (Usual Care): Patients receive standard hospital discharge instructions without additional messaging.
Intervention Arm: Patients receive structured follow-up messages using existing education materials via MyChart and automated text messaging within 24, 48, and 72 hours post-discharge. Patients in the control arm who experience a subsequent cancer treatment related ED visit without documented OAC engagement will be crossed over to the intervention arm.
Messaging Intervention:
Patients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish).
Outcome Tracking:
The study team will monitor patient medical records for the following:
Follow-up will occur in 3-month intervals. Patients who engage with the OAC clinic will be removed from the observation list and considered to have completed the study. If a patient has another ED visit without OAC engagement, the observation period will repeat.
Data Collection:
Data will be extracted from Epic and include:
Data Analysis Plan:
Descriptive statistics will be used to summarize engagement and outcome data. Time-to event analyses (Kaplan-Meier curves with Cox proportional hazards models) will be used to compare time to ED arrival between arms. Mixed-effects logistic regression will be used to analyze secondary visit county outcomes. Subgroup analyses will explore differential effects by language, cancer type, and prior ED utilization.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients randomized to the intervention arm will receive structured follow-up messages aimed at increasing awareness and utilization of Oncology Acute Care (OAC) services. Messaging will be delivered via both MyChart and automated text messages, tailored to the patient's preferred language (English or Spanish).
Time frame: 2 years maximum
Evaluate whether structured MyChart + text messaging after hospital/ED discharge decreases time to the next cancer treatment-related ED visit compared with usual care.
Time frame: 2 years maximum
Assess whether messaging increases patient engagement with the Oncology Acute Care triage line or clinic before returning to the ED.
Time frame: 2 years maximum
Measure message engagement metrics (viewed, unviewed, and response rates).
Time frame: 2 years maximum
Evaluate feasibility and implementation fidelity of the messaging workflow within Parkland's Epic environment.
Time frame: 2 years maximum
Identify patient subgroups (e.g., language, cancer type, prior ED utilization) where the intervention has the greatest effect on ED utilization or care engagement.
Contact information is provided by the study sponsor or research team.
Arthur Hong, MD, MPH
CONTACT
Kathryn Anderson, MA
CONTACT
University of Texas Southwestern Medical Center
Other
A Pragmatic Randomized Controlled Crossover Study to Evaluate the Impact of Messaging Interventions on Emergency Department Utilization Among Oncology Patients at Parkland Health
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07739563
Behavior, Breast Cancer
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07739849
Cancer, Hemic and Lymphatic Diseases
View Trial DetailsNCT07735442
Cancer, Neoplasms
Boston, Massachusetts, United States
View Trial DetailsNCT07731425
Cancer, Neoplasms
Boston, Massachusetts, United States
View Trial Details